Mark Sullivan
CIK 1331843 · Chief Legal Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.23M
Companies
4
Total Filings
34
Lifetime Open-Market Net
-$1.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Legal Officer | 320,571 | $44.39 | $14.23M | -$783.4K | 4 | 2026-06-26 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Legal Officer | 282,576 | $15.00 | $4.24M | -$569.9K | 10 | 2025-12-29 |
| Carisma Therapeutics Inc. (SESN) Delisted | General Counsel & Secretary | 19,186 | $12.58 | $241.3K | -$152.1K | 6 | 2023-03-06 |
| MModal Inc. (MEDH) Delisted | Gen Counsel, CCO & Secretary | 39,268 | — | — | -$43.7K | 5 | 2012-01-04 |
Recent Filings · Page 2 of 4
34 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,491 | -$78.1K | EDGAR |
| 2025-06-25 | DFTX | Notice (144) | −11,491 | -$78.2K | EDGAR |
| 2025-03-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −6,576 | -$44.3K | EDGAR |
| 2025-03-25 | DFTX | Notice (144) | −6,576 | -$44.3K | EDGAR |
| 2025-03-13 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2024-12-27 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −4,519 | -$33.6K | EDGAR |
| 2024-12-26 | DFTX | Notice (144) | −4,519 | -$33.6K | EDGAR |
| 2024-09-25 | DFTX | Notice (144) | −4,430 | -$26.5K | EDGAR |
| 2024-09-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −4,430 | -$26.5K | EDGAR |
| 2024-06-25 | DFTX | Notice (144) | −17,854 | -$129.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.